A study that evaluated an investigational dosage of once-daily ledipasvir 45 mg/sofosbuvir 200 mg (LDV/SOF) in children aged six to 11 years infected with HCV, found that 99 percent of children had undetectable levels of HCV-RNA 12 weeks after treatment, report researchers. The study showed that the fixed-dose combination of LDV/SOF was well-tolerated, and no patients experienced serious adverse events related to the study drug.